Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflexal V 2013/2014 Immunogenicity and Safety
NCT01893177Phase 3Completed
- Sponsor
- Crucell
- Start
- Jul 2013
- Primary completion
- Aug 2013
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Inflexal V in influenza (2 arms), sponsored by Crucell. Primary endpoints: Percentage of subjects with seroconversion at Day 22, Percentage of subjects with seroprotection at Day 22 and 1 more. Started Jul 2013; status: completed.
02
Drugs
Inflexal V
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01893177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893177.